Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide
Authors' conclusion
Tirzepatide produced meaningful weight loss across groups but outcomes varied based on weight-reduction status, T2D status, and prior response to semaglutide.
Study context
- Population
- Adults treated with tirzepatide between May 2022 and January 2023; 65% female; mean age 52 years; mean BMI 36.15 kg/m²of 941 charts
- Participants
- 293 adults
- Exposure
- Weight-reduced vs non-weight-reduced patients treated with tirzepatide
- Weight-reducedn = 133
- Non-weight-reducedn = 160reference
- Outcome
- Weight-loss outcomes (% TBW lost)
- Follow-up
- 6 months
Main finding
As reported in the abstract
% TBW lost
P < 0.001
Observational data: associations, not effects.
Further findings
% TBW lost by reason for switching from semaglutide · plateau n = 28; non-responders n = 33
P < 0.001
% total body weight (TBW) lost, stratified by T2D status
- Difference remained significant among patients without T2D
% TBW lost in patients switched from semaglutide due to non-response or plateau
- Switched from semaglutide (n = 61), TBW lost
- 5.3%
Original publication
Real‐World Weight‐Loss Outcomes in Weight‐Reduced Patients Treated With Tirzepatide. Obesity (Silver Spring). Published 28 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →